SCHEMBL17370574

SCHEMBL17370574

C=C(C)C(=O)Oc1ccc(C#Cc2c(OC(=O)C(=C)C)cc(C#Cc3ccc(-c4ccc(OC(=O)C(=C)C)cc4)cc3)cc2OC(=O)C(=C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.47
KMT2A Q03164 2/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
APP P05067 1/20 0.34
FFAR1 O14842 5/20 0.34
TDP1 Q9NUW8 2/20 0.34
MAPT P10636 1/20 0.34
POLB P06746 1/20 0.34
APEX1 P27695 1/20 0.34
HTT P42858 1/20 0.34
ACACB O00763 4/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
PTPN1 P18031 1/20 0.33
BACE1 P56817 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17370256 0.96 ELANE (0.50) ELANEKMT2AATMAPPFFAR1
SCHEMBL17370514 0.95 ELANE (0.47) ELANEKMT2AATMHSD17B10LMNA
SCHEMBL17370680 0.95 ELANE (0.47) ELANEKMT2AATMHSD17B10LMNA
SCHEMBL17370555 0.93 ELANE (0.41) ELANEKMT2AATMHSD17B10LMNA
SCHEMBL17370575 0.92 ELANE (0.40) ELANEKMT2AATMHSD17B10LMNA
SCHEMBL17370573 0.92 ELANE (0.40) ELANEKMT2AATMHSD17B10LMNA
SCHEMBL17370576 0.92 ELANE (0.40) ELANEKMT2AATMHSD17B10LMNA
SCHEMBL17370571 0.91 ELANE (0.39) ELANEKMT2AATMHSD17B10LMNA
SCHEMBL17370617 0.89 ELANE (0.43) ELANEKMT2AATMHSD17B10LMNA
SCHEMBL17370734 0.88 ELANE (0.50) ELANEKMT2AATMHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708534-B2 Polymerizable compound having triple bond, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2017-07-18 US disclosed
US-9708534-B2 Polymerizable compound having triple bond, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2017-07-18 US disclosed
US-20150376505-A1 POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2015-12-31 US disclosed
US-20150376505-A1 POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2015-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376505-A1 POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CCNT1, CCNA1, CCND1 ELANE 2133/4885KMT2A 3636/4885ATM 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.